Citius Pharmaceuticals Inc Total Liabilities
Citius Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Citius Pharmaceuticals Inc (CTXR) has total liabilities worth $63.46 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Citius Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Citius Pharmaceuticals Inc (2011–2025)
Total liabilities of Citius Pharmaceuticals Inc from 2011 to 2025. This chart illustrates how Citius Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Citius Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Citius Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
InfoBank Corporation
KQ:039290
|
Korea | ₩28.87 Billion |
|
SenzaGen AB
ST:SENZA
|
Sweden | Skr24.13 Million |
|
Neurosense Therapeutics Ltd
NASDAQ:NRSN
|
USA | $2.59 Million |
|
Raptis Group Ltd
AU:RPG
|
Australia | AU$62.52K |
|
Freeport Resources Inc
V:FRI
|
Canada | CA$93.15K |
|
West Coast Silver Ltd
AU:WCE
|
Australia | AU$1.16 Million |
|
FORIS AG
F:FRS
|
Germany | €3.26 Million |
|
Konsolidator AS
CO:KONSOL
|
Denmark | Dkr29.28 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Citius Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Citius Pharmaceuticals Inc balance sheet assets.
Liquidity & Leverage Metrics
Citius Pharmaceuticals Inc Total Liabilities Ratios Explained
Citius Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Citius Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Citius Pharmaceuticals Inc (2011–2025)
The table below shows the annual total liabilities of Citius Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $53.41 Million | +25.52% |
| 2024-09-30 | $42.55 Million | +249.35% |
| 2023-09-30 | $12.18 Million | +15.20% |
| 2022-09-30 | $10.57 Million | +9.61% |
| 2021-09-30 | $9.65 Million | -4.52% |
| 2020-09-30 | $10.10 Million | +119.26% |
| 2019-09-30 | $4.61 Million | +44.68% |
| 2018-09-30 | $3.18 Million | +28.98% |
| 2017-09-30 | $2.47 Million | -52.37% |
| 2016-09-30 | $5.18 Million | +276.54% |
| 2015-09-30 | $1.38 Million | -40.13% |
| 2014-09-30 | $2.30 Million | +15548.54% |
| 2013-09-30 | $14.69K | -68.04% |
| 2012-09-30 | $45.98K | +91.17% |
| 2011-09-30 | $24.05K | -- |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-… Read more